You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Resonant-Photonic-Device-Enhanced SERS Substrate with Pinpointed Plasmonic-Active

    SBC: OMEGA OPTICS, INC.            Topic: NIEHS

    DESCRIPTION (provided by applicant): The use of Surface Enhanced Raman Scattering (SERS) for biomolecule detection has been restricted due to the great difficulty of fabricating ultrasensitive and reproducible surface-plasmonic-resonance (SPR) substrates.Therefore, detecting extremely small amount of biomolecules for clinical application is significantly limited. In this STTR Phase II research, w ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Remote focusing through spatial light modulation for multifocal multiphoton micro

    SBC: BOULDER NONLINEAR SYSTEMS, INC.            Topic: NIMH

    DESCRIPTION (provided by applicant): Nonlinear optical microscopy techniques (such as two-photon florescence) are being used to acquire volumetric (i.e. three dimensional) images that probe several hundred microns into scattering tissue. These techniques are being combined with fast acquisition schemes to allow imaging of live, moving specimens at high NA. This combination allows for high-resoluti ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Recognition and Referral Skills for RAs- Alcohol-Drug Problems

    SBC: PHASE 5, INC.            Topic: NIAAA

    DESCRIPTION (provided by applicant): Resident assistants (RAs) are often the first staff members at a college or university to learn that a student is engaged in alcohol or other drug abuse. This Phase II STTR application seeks support to further develop and test a web-based program called RA Resources (RAR) - Alcohol-Drug Problems. Phase 5, Inc. will conduct this theory-driven research project ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  4. Real-Time Optical Feedback for the Control of In Vivo Nanoparticle Concentration

    SBC: NANOSPECTRA BIOSCIENCES, INC.            Topic: NIMHD

    DESCRIPTION (provided by applicant): There is an immediate and urgent clinical need to enhance the monitoring of the delivery and accuracy of targeted drug delivery, the onset and spread of cancers, and the longitudinal monitoring of cancer treatments. Nanotechnology holds the promise to address this problem. A smart particle capable of selective targeting would augment the physician's tools nee ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  5. Rapid, noninvasive diagnosis and monitoring of shock

    SBC: NONINVASIX, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Assessment and management of circulatory shock in critically ill patients requires rapid measurement of two critical variables: mixed venous oxyhemoglobin saturation (venous SO2) and total blood hemoglobin concentration [Hgb] to identify insufficient oxygen delivery and anemia and to determine the need for therapy with fluids, inotropic or vasodilator drugs or ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  6. Rapid Development of a Highly Specific Dengue Diagnostic Test

    SBC: Z-Quick, LLC            Topic: NIAID

    Project Summary Abstract The advent of the Zika virusZIKVepidemic around the world has and will cause problems for the correct diagnosis of flavivirus infectionsFor many yearsDENV serological diagnosis was relatively straightforwardHoweverafter the recent ZIKV epidemiccross reactive antibodiesAbsgenerated after ZIKV infection will bind to DENV even if the patient has never had DENVThe only FDA app ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. rAAV5-hCNGB3 Gene Therapy for Achromatopsia: Safety and Efficacy in a Dog Model

    SBC: APPLIED GENETIC TECHNOLOGIES CORPORATION            Topic: N

    DESCRIPTION provided by applicant Complete achromatopsia is an autosomal recessive inherited congenital disorder of retinal cone photoreceptors Patients with complete achromatopsia experience extreme light sensitivity and daytime blindness and best visual acuity under non bright light conditions is usually or worse and generally stable over time In addition to poor acuity hypersensit ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Production and Characterization of Human Immunoglobulin Producing Goats for Diagnostic Reagents and Therapeutics

    SBC: SAB CAPRA, LLC            Topic: NIAID

    Project Summary/Abstract The ultimate goal of this phase II STTR proposal is to expand the capabilities of SABandapos;s diversitAb™ platform by continuing advanced development of Transchromosomic goats (TcGs). This will be accomplished by producing male and female goat endogenous immunoglobulin gene knockout cell lines that contain SAB Capraandapos;s human artificial chromosome (HAC) which encod ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Preparation and Characterization of 2nd Generation HIV-1 Maturation Inhibitor Dru

    SBC: DFH Pharma, Inc            Topic: NIAID

    DESCRIPTION (provided by applicant): Despite advances in the development of HIV drugs there remains a need for new therapies. Toxicities associated with long term use of many of the approved HIV drugs coupled with the development of resistance drives the need for new and novel antivirals. Maturation inhibitors (MIs) represent one such class of HIV therapies. HIV maturation inhibitors block virus r ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Preclinical studies to validate the efficacy of novel mechanism-of-action small molecule inhibitors to treat Duchenne muscular dystrophy

    SBC: RIDGELINE THERAPEUTICS LLC            Topic: NIAMS

    Progressive muscle weakness and degeneration is a hallmark of Duchenne muscular dystrophyDMDIn DMD patientsthe lack of dystrophin reduces muscle fiber structural integritymaking muscles vulnerable to persistent injury and damageRepairing these damaged muscles requires the continual activation of muscle stem cellsmuSCwhich leads to muSC dysfunction and senescenceand ultimately the muscle degenerati ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government